Index RUT
P/E -
EPS (ttm) -0.61
Insider Own 20.91%
Shs Outstand 135.04M
Perf Week -9.81%
Market Cap 139.32M
Forward P/E -
EPS next Y -0.69
Insider Trans -0.14%
Shs Float 119.79M
Perf Month 57.46%
Income -82.68M
PEG -
EPS next Q -0.29
Inst Own 41.50%
Short Float 17.92%
Perf Quarter -12.39%
Sales 126.85M
P/S 1.10
EPS this Y -5.30%
Inst Trans 12.84%
Short Ratio 4.29
Perf Half Y -23.34%
Book/sh -0.39
P/B -
EPS next Y 26.68%
ROA -27.04%
Short Interest 21.46M
Perf Year -81.34%
Cash/sh 0.73
P/C 1.25
EPS next 5Y -
ROE -538.57%
52W Range 0.54 - 6.26
Perf YTD -34.29%
Dividend Est. -
P/FCF -
EPS past 5Y 18.22%
ROI -56.78%
52W High -85.31%
Beta 1.90
Dividend TTM -
Quick Ratio 1.25
Sales past 5Y 386.36%
Gross Margin 89.59%
52W Low 70.35%
ATR (14) 0.13
Dividend Ex-Date -
Current Ratio 1.68
EPS Y/Y TTM 73.88%
Oper. Margin -61.09%
RSI (14) 50.82
Volatility 11.91% 15.44%
Employees 233
Debt/Eq -
Sales Y/Y TTM 2380.87%
Profit Margin -65.18%
Recom 1.86
Target Price 6.20
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 51.42%
Payout -
Rel Volume 0.40
Prev Close 0.92
Sales Surprise -100.00%
EPS Surprise 20.98%
Sales Q/Q 100.00%
Earnings May 08 BMO
Avg Volume 5.01M
Price 0.92
SMA20 0.35%
SMA50 12.18%
SMA200 -42.35%
Trades
Volume 1,979,435
Change -0.49%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-26-23 Resumed
Oppenheimer
Outperform
$12
Apr-21-23 Initiated
JP Morgan
Neutral
$7
Jul-23-21 Downgrade
Goldman
Neutral → Sell
$24 → $7
May-18-21 Resumed
Goldman
Neutral
$24
Mar-05-21 Upgrade
Chardan Capital Markets
Neutral → Buy
$30
Sep-18-20 Downgrade
Chardan Capital Markets
Buy → Neutral
$32.50 → $27.50
Aug-18-20 Initiated
Piper Sandler
Overweight
$40
Aug-11-20 Upgrade
Jefferies
Hold → Buy
$4 → $29
Aug-11-20 Reiterated
H.C. Wainwright
Buy
$8 → $41
Apr-30-19 Initiated
Jefferies
Hold
$7
Oct-22-18 Initiated
Chardan Capital Markets
Buy
$15
Oct-13-17 Initiated
Oppenheimer
Outperform
$19
Aug-04-17 Reiterated
H.C. Wainwright
Buy
$15 → $19
Feb-01-17 Reiterated
FBR & Co.
Outperform
$23 → $18
Aug-12-16 Reiterated
FBR Capital
Outperform
$43 → $23
Aug-01-16 Reiterated
H.C. Wainwright
Buy
$50 → $15
Aug-01-16 Downgrade
BofA/Merrill
Buy → Neutral
Jul-29-16 Resumed
H.C. Wainwright
Buy
$50
Mar-30-16 Initiated
FBR Capital
Outperform
$40
Mar-03-16 Initiated
Guggenheim
Buy
Show Previous Ratings
May-13-24 12:18PM
May-09-24 11:06AM
07:00AM
06:30AM
03:11AM
11:54AM
Loading…
May-08-24 11:54AM
08:42AM
07:25AM
(Associated Press Finance)
07:00AM
May-06-24 04:01PM
09:30AM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Mar-28-24 07:00AM
Mar-19-24 08:30AM
07:00AM
Loading…
07:00AM
Mar-13-24 03:32PM
08:17AM
Mar-07-24 11:48AM
Mar-06-24 02:17AM
(Thomson Reuters StreetEvents)
Mar-05-24 09:51AM
07:32AM
07:00AM
Feb-28-24 07:00AM
Feb-27-24 07:00AM
Feb-26-24 07:00AM
Jan-17-24 07:00AM
Jan-09-24 08:44AM
07:00AM
Jan-08-24 06:30AM
06:30AM
Loading…
06:30AM
Jan-04-24 04:00PM
Dec-07-23 07:46PM
Nov-28-23 09:18AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-05-23 02:22PM
Nov-02-23 08:47AM
07:32AM
(Associated Press Finance)
07:00AM
Nov-01-23 10:30AM
Oct-30-23 05:30PM
Oct-19-23 10:30AM
Oct-12-23 07:00AM
Oct-06-23 07:00AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-08-23 07:00AM
Sep-07-23 10:00AM
Aug-29-23 09:00AM
Aug-09-23 06:27AM
Aug-08-23 08:25AM
07:19AM
(Associated Press Finance)
07:00AM
Aug-04-23 07:00AM
Aug-01-23 07:00AM
07:00AM
Jul-14-23 04:01PM
Jul-07-23 10:17AM
Jun-21-23 09:00AM
Jun-17-23 03:45PM
Jun-09-23 07:00AM
07:00AM
Jun-05-23 07:00AM
Jun-02-23 07:00AM
May-30-23 04:00PM
May-16-23 06:00AM
May-10-23 07:00AM
May-09-23 08:15AM
07:07AM
07:00AM
07:00AM
May-08-23 07:00AM
02:32AM
May-05-23 07:00AM
Apr-29-23 09:03AM
Apr-27-23 10:03AM
07:00AM
06:37AM
(American City Business Journals)
Apr-26-23 07:46PM
06:23PM
10:02AM
Apr-24-23 02:09AM
Apr-20-23 09:45AM
Apr-14-23 05:10AM
Apr-07-23 07:00AM
Apr-04-23 04:30PM
Mar-22-23 03:44AM
Mar-09-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 10:28PM
(Thomson Reuters StreetEvents)
08:25AM
07:00AM
Mar-03-23 04:00PM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-14-23 07:00AM
Feb-08-23 07:28AM
Feb-03-23 11:30AM
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shaff Eric D. CEO and President May 15 '24 Sale 0.94 2,435 2,289 140,698 May 17 08:18 PM Ege David S. See Remarks May 15 '24 Sale 0.94 1,090 1,025 75,734 May 17 08:16 PM von Moltke Lisa See Remarks May 15 '24 Sale 0.94 939 883 19,017 May 17 08:23 PM Henn Matthew R. See Remarks May 15 '24 Sale 0.94 891 838 65,357 May 17 08:17 PM DesRosier Thomas Chief Legal Officer and EVP May 15 '24 Sale 0.94 843 792 122,390 May 17 08:14 PM Young Teresa L. See Remarks May 15 '24 Sale 0.94 703 661 17,658 May 17 08:18 PM Shaff Eric D. CEO and President Feb 16 '24 Sale 1.08 11,549 12,473 135,321 Feb 16 09:42 PM Ege David S. See Remarks Feb 16 '24 Sale 1.08 5,010 5,411 73,856 Feb 16 09:15 PM von Moltke Lisa See Remarks Feb 16 '24 Sale 1.08 4,400 4,752 16,988 Feb 16 09:21 PM Henn Matthew R. See Remarks Feb 16 '24 Sale 1.08 4,170 4,504 63,436 Feb 16 09:31 PM Arkowitz David Chief Financial Officer Feb 16 '24 Sale 1.08 3,939 4,254 182,442 Feb 16 09:13 PM DesRosier Thomas Chief Legal Officer and EVP Feb 16 '24 Sale 1.08 3,939 4,254 120,577 Feb 16 09:48 PM Young Teresa L. See Remarks Feb 16 '24 Sale 1.08 3,374 3,644 15,705 Feb 16 09:29 PM Shaff Eric D. CEO and President Oct 30 '23 Sale 1.35 8,552 11,545 115,620 Oct 31 09:40 PM von Moltke Lisa See Remarks Oct 30 '23 Sale 1.35 4,232 5,713 9,513 Oct 31 09:36 PM DesRosier Thomas Chief Legal Officer and EVP Oct 30 '23 Sale 1.35 4,156 5,611 113,891 Oct 31 09:39 PM Arkowitz David Chief Financial Officer Oct 30 '23 Sale 1.35 4,066 5,489 175,756 Oct 31 09:39 PM Ege David S. See Remarks Oct 30 '23 Sale 1.35 4,066 5,489 66,991 Oct 31 09:39 PM Henn Matthew R. See Remarks Oct 30 '23 Sale 1.35 3,886 5,246 56,356 Oct 31 09:36 PM Young Teresa L. See Remarks Oct 30 '23 Sale 1.35 2,907 3,924 8,454 Oct 31 09:40 PM Cloghessy Paula See Remarks Oct 30 '23 Sale 1.35 2,904 3,920 45,684 Oct 31 09:43 PM Young Teresa L. See Remarks Oct 27 '23 Option Exercise 0.00 11,361 0 11,361 Oct 31 09:40 PM Cloghessy Paula See Remarks Oct 27 '23 Option Exercise 0.00 9,418 0 48,588 Oct 31 09:43 PM Shaff Eric D. CEO and President Oct 27 '23 Option Exercise 0.00 27,838 0 124,172 Oct 31 09:40 PM Arkowitz David Chief Financial Officer Oct 27 '23 Option Exercise 0.00 13,209 0 179,822 Oct 31 09:39 PM Ege David S. See Remarks Oct 27 '23 Option Exercise 0.00 11,361 0 71,057 Oct 31 09:39 PM DesRosier Thomas Chief Legal Officer and EVP Oct 27 '23 Option Exercise 0.00 13,501 0 118,047 Oct 31 09:39 PM Henn Matthew R. See Remarks Oct 27 '23 Option Exercise 0.00 12,623 0 60,242 Oct 31 09:36 PM von Moltke Lisa See Remarks Oct 27 '23 Option Exercise 0.00 13,745 0 13,745 Oct 31 09:36 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite